Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
Key Details
- 1Lucida Medical, a UK-based AI firm, raised $11.4 million in new funding.
- 2Their Prostate Intelligence (Pi) software uses MRI to help diagnose prostate cancer.
- 3The software is already deployed in up to 15 UK NHS hospitals.
- 4NHS invested around $3 million to use the platform, aiming for diagnoses within 28 days.
- 5The new funds will help pursue US FDA regulatory approval and expand to detect other clinical conditions.
Why It Matters
This funding supports efforts to scale AI-powered prostate cancer diagnosis, addressing critical radiology workforce shortages and speeding up patient pathways. US FDA approval could open access to broader markets and bring innovative diagnostic AI tools to more clinicians and patients.
Source
Radiology Business
Related News
•AuntMinnie
Deep Learning Model Predicts Brain Tumor MRI Enhancement Without Gadolinium
German researchers developed a deep learning approach to predict MRI contrast enhancement in brain tumors without the need for gadolinium-based agents.
•Radiology Business
Study Highlights Limitations of AI in Prostate MRI Screening
New research points to several shortcomings in implementing AI for MRI-based prostate cancer screening.
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.